SEC Form 4 · accession 0001127602-19-001657
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & CEO · Director
Period of report
Jan 7, 2019
Accepted (ET)
Jan 9, 2019 · 8:02 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 7, 2019 | M | 7,055 | $52.65 | A | 7,195 | D | |
| Common StockF2 | Jan 7, 2019 | S | 1,300 | $112.5392 | D | 5,895 | D | |
| Common StockF3 | Jan 7, 2019 | S | 4,875 | $113.5097 | D | 1,020 | D | |
| Common StockF4 | Jan 7, 2019 | S | 880 | $114.0857 | D | 140 | D | |
| Common Stock | Jan 8, 2019 | M | 7,054 | $52.65 | A | 7,194 | D | |
| Common StockF5 | Jan 8, 2019 | S | 3,300 | $112.8021 | D | 3,894 | D | |
| Common StockF6 | Jan 8, 2019 | S | 3,654 | $113.433 | D | 240 | D | |
| Common Stock | Jan 8, 2019 | S | 100 | $114.89 | D | 140 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 683,489 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $52.65 | Jan 7, 2019 | M | 7,055 | D | Dec 31, 2009 | Dec 31, 2019 | Common Stock | 7,055 | 134,028 | D |
| Stock Options | $52.65 | Jan 8, 2019 | M | 7,054 | D | Dec 31, 2009 | Dec 31, 2019 | Common Stock | 7,054 | 126,974 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 148,138 stock options (which expire at the end of 2019) during the month of January 2019, in equal tranches of approximately 7,055 shares per day assuming certain conditions are met.
- F2This transaction was executed in multiple trades at prices ranging from $111.94 to $112.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $112.96 to $113.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $113.98 to $114.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $112.15 to $113.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $113.15 to $114.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.